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influenza: A CHAID decision-tree anaSummary Objectives: To define which variables upon ICU admission could be related to the
presence of coinfection using CHAID (Chi-squared Automatic Interaction Detection) analysis.
Methods: A secondary analysis from a prospective, multicentre, observational study (2009
e2014) in ICU patients with confirmed A(H1N1)pdm09 infection. We assessed the potential
of biomarkers and clinical variables upon admission to the ICU for coinfection diagnosis using
CHAID analysis. Performance of cut-off points obtained was determined on the basis of the bi-
nominal distributions of the true (þ) and true () results.
Results: Of the 972 patients included, 196 (20.3%) had coinfection. Procalcitonin (PCT; ng/mL
2.4 vs. 0.5, p < 0.001), but not C-reactive protein (CRP; mg/dL 25 vs. 38.5; pZ 0.62) was high-
er in patients with coinfection. In CHAID analyses, PCT was the most important variable for co-
infection. PCT <0.29 ng/mL showed high sensitivity (Se Z 88.2%), low Sp (33.2%) and high
negative predictive value (NPVZ 91.9%). The absence of shock improved classification capac-
ity. Thus, for PCT <0.29 ng/mL, the Se was 84%, the Sp 43% and an NPV of 94% with a post-test
probability of coinfection of only 6%.
Conclusion: PCT has a high negative predictive value (94%) and lower PCT levels seems to be a
good tool for excluding coinfection, particularly for patients without shock.
ª 2015 The British Infection Association. Published by Elsevier Ltd. All rights reserved.Introduction
Community-acquired respiratory coinfection (CARC) in pa-
tients with viral pneumonia caused by influenza A(H1N1)
pdm09 has been recognised as a major cause of influenza-
related death.1,2 Since 2009, more than 2000 patients have
been admitted to intensive care units (ICUs) for cases of se-
vere influenza in Spain.3e6 To reducemortality andmorbidity
in this vulnerable patient population, early administration of
antibiotic (AB) treatment is recommended in patients sus-
pected of having CARC. Yet, different studies have found
that both clinical signs and symptoms, and commonly used
laboratory markers, are unreliable for assessing the risk of
CARC in this particular subset of patients admitted to the
ICU.7,8 As a result, in clinical practice, currently most pa-
tients receive antibiotics (AB); according to the Spanish Soci-
ety of Intensive Care Medicine (SEMICYUC) database, 100% of
critically ill patients with influenza were treated with empir-
ical AB upon admission to the ICU.3e6 However, only in 20% of
the cases was CARC eventually confirmed.6 More accurate,
prompt diagnostic tools to rule out CARC could potentially
limit AB overuse and subsequently reduce unnecessarily
high costs, potential side-effects and the development of
multi-drug resistance infections.
Procalcitonin (PCT) is a biomarker reported in the event
of bacterial infection and adequately correlates with
severity and outcome of lower respiratory tract infections
(LRTI). In addition, AB guidelines, based on PCT levels, have
been seen to significantly reduce AB administration indrı´guez AH, et al., Procalcitonin (P
lysis, J Infect (2015), http://dx.dpatients with LRTI in both emergency departments and
ICUs.9e11 However, there is a lack of large-scale clinical
data demonstrating the utility of PCT as an accurate
biomarker for guiding AB use in patients with severe influ-
enza pneumonia with CARC. Four minor studies have sug-
gested that the use of PCT cut-off ranges in patients
infected with influenza A(H1N1)pdm09 may estimate the
probability of developing CARC.12e15 Nevertheless, these
studies are limited in terms of small sample size (between
16 and 100 patients) and different criteria for patient selec-
tion, cut-offs, and outcome. The aim of this study was to
evaluate the potential role of PCT in ruling out the presence
of CARC in a large, well-defined cohort of influenza A(H1N1)
pdm09-infected patients. Our hypothesis was that the PCT
algorithms recommended for AB administration9 could be
different from those observed in patients with primary viral
pneumonia caused by influenza A(H1N1)pdm09. The main
objective of our study was, therefore, to define which vari-
ables upon admission to the ICU could be related to the
presence of CARC using CHAID (Chi-squared Automatic
Interaction Detection) decision-tree analysis16e18 in order
to maximise the probability of a correct diagnosis.16e19
Material and methods
Study design and patient population
This is a secondary analysis from a prospective, observa-
tional cohort study conducted across 148 ICUs in SpainCT) levels for ruling-out bacterial coinfection in ICU patients with
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Procalcitonin and bacterial coinfection 3between June 2009 and April 2014. Data were obtained
from a voluntary register created by the SEMICYUC.3e6
The study was approved by the Joan XXIII University
Hospital Ethics Committee (IRB NEUMAGRIP/11809). Pa-
tients remained anonymous. The requirement for informed
consent was waived due to the observational nature of the
study and the fact that this activity was considered an
emergency public health response, as reported else-
where.3e6 Three time periods were considered: 1) 2009
pandemic infection period (epidemiological weeks [EW]
23e52); 2) the post-pandemic period (EW 50e52 of 2010
and 1e9 of 2011); and 3) 2014 winter season period (EW
40e52 of 2013 and 1e14 of 2014). During these periods,
all patients admitted to the ICU with influenza symptoms
were systematically tested to confirm influenza A(H1N1)
pdm09. Only patients with PCT measurements upon admis-
sion to the ICU were included in this analysis. Children un-
der 15 years of age were not enrolled in the register
Influenza A(H1N1)pdm09 virus infection was confirmed by
real-time reverse-transcription-polymerase chain reaction
(rt-PCR) in all patients. The rt-PCR methods and further de-
tails are described elsewhere.3e6
Patient flow and outcome assessment
ICU admission criteria and treatment decisions for all pa-
tients, including theneed for intubationand typeof antibiotic
or antiviral therapy administered, were made at the discre-
tion of the attending physician and not standardised. Septic
shock and multiple organ dysfunction score (MODS) were
defined following the international criteria.20 Organ failure
was assessed using the sequential organ failure assessment
(SOFA) scoring system.21 Only patients with microbiological
confirmation of CARC were included in this analysis.
Definitions
Primary viral pneumonia caused by influenza A(H1N1)
pdm09 was defined as patients presenting with acute
respiratory distress, unequivocal alveolar opacities
involving two or more lobes, and negative respiratory and
blood bacterial cultures during the acute phase of influenza
virus infection.3e6 The presence of CARC was defined as a
bacterial respiratory microbiologically-confirmed infection
diagnosed within the first two days of hospitalisation. For
CARC diagnosis an acute pulmonary infiltrate evident on
chest radiographs and consistent with pneumonia and
confirmatory findings on clinical examination were
required.6 Infections occurring later were considered noso-
comial. Hospital-acquired pneumonia (HAP) was defined
based on current guidelines22 and excluded for this study.
An organism was considered to be the definitive causa-
tive pathogen only if it could be isolated from blood or
pleural fluid.3e6 Other microorganisms isolated from quan-
titative endotracheal aspirate (ETA), bronchoalveolar
lavage (BAL) or protected specimen brush (PSB) were
considered “probable” pathogens. Serology tests revealing
a fourfold increase in antibody levels were also considered
as definitive diagnoses. A positive urinary antigen test for
Streptococcus pneumoniae or Legionella was considered
probable causative pathogen.Please cite this article in press as: Rodrı´guez AH, et al., Procalcitonin (
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on the demonstration of microorganisms in histopathology
samples. Patients with a halo or an air-crescent sign on
their lung computed tomography (CT) scan were considered
to have probable pulmonary aspergillosis. Colonization was
defined as the isolation of Aspergillus spp. in lower respira-
tory samples in patients not meeting the European Organi-
zation for Research and Treatment of Cancer23 or Bulpa’s
criteria.24 Legionella and pneumococcal urinary antigen
were determined in all patients upon admission to the
ICU. In patients receiving mechanical ventilation, a respira-
tory specimen was obtained upon admission to the ICU ac-
cording to local protocols. Obese patients were defined as
those whose body mass index (BMI) exceeds 30 kg/m2.3e6
Acute kidney injury (AKI) definition and staging were estab-
lished according to the current Acute Kidney Injury Network
classification.25 Shock was defined as the need for a vaso-
pressor for more than 4 h after fluid replacement at the
time of admission to the ICU.20
Laboratory testing
Procalcitonin is not part of the standard protocol for the
diagnosis of community-acquired pneumonia Spain. The
decision to measure serum PCT upon admission to the ICU
was left to the discretion of the attending physician and
was not standardised. PCT was measured using
B$R$A$H$M$S PCT automated immunoassays. The analytical
sensitivity of all assays was <0$05 mg/L. All techniques
were based on a one-step immunoassay sandwich method
determined either by chemiluminescence or fluorescence.
Statistical analysis
Discrete variables are expressed as counts (percentage) and
continuous variables, as means and standard deviation (SD),
or medians with the 25th to 75th interquartile range (IQR).
For patients’ demographic and clinical characteristics,
differences between groups were assessed using the chi-
squared test or Fisher’s exact test for categorical variables
and, Student’s t-test or the ManneWhitney U test for
continuous and ordinal variables when appropriate.
Receiver operating characteristic (ROC) curves were built
to establish the accuracy of the PCT and CRP (C-reactive
protein) values in the identification of CARC. Differences
between by the area under the receiver operating charac-
teristic curve (ROC-AUC) were obtained by Hanley and
McNeil analysis. The sensitivity (S), specificity (Sp), positive
and negative predictive values (PPV, NPV) and positive or
negative likelihood ratio (LRþ, LR) were calculated
considering the PCT cut-off levels used in the previously re-
ported algorithm.26 Four cut-off points were analysed: 1)
PCT <0$25 ng/mL; 2) PCT <0$50 ng/mL; 3) PCT
<0$75 ng/mL; and 4) PCT >1$0 ng/mL on the basis of the
binominal distributions of the true positive and true nega-
tive results. Subsequently, we convert pre-test probability
to “pre-test Odds” (Pre-test Prob/[1Pre-test Prob]),
then multiply the Pre-test Odds by the LR for the finding
to derive the “post-test Odds” and then convert Post-test
Odds back to “Post-test probability” using (Post-test
Odds/[1þPost-test Odds]).PCT) levels for ruling-out bacterial coinfection in ICU patients with
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A CHAID tree is a graphic representation of a series of
decision rules. Beginning with a root node that includes all
cases, the tree branches are divided into different child
nodes that contain a subgroup of cases. The criterion for
branching (or partitioning) is selected after examining all
possible values of all available predictive variables. In the
terminal nodes, a grouping of cases is obtained, such that
the cases are as homogeneous as possible with respect to
the value of the dependent variable.16e18 CHAID decision
trees are nonparametric procedures that make no assump-
tions of the underlying data. This algorithm determines how
continuous and/or categorical independent variables best
combine to predict a binary outcome based on “if-then”
logic by portioning each independent variable into mutually
exclusive subsets based on data homogeneity (additional in-
formation about the CHAID algorithm in the supplemental
digital content). For this study, the response variable is
the presence or absence of CARC. S, Sp, PPV, NPV and
LRþ or LR were calculated considering the PCT CHAIDTable 1 Comparison of demographic and clinical characteristic
tion with or without community-acquired respiratory coinfection
Variables Overall (n Z 972)
Demographics
Age, mean (SD) 51.2 (14.8)
Median (IQR) 52.0 (40e61)
Male, n (%) 581 (59.8)
Severity of illness
APACHE II score, median (IQR) 16.5 (11e21)
SOFA score, median (IQR) 6.4 (4e9)
Comorbidities, n (%) 712 (73.6)
Asthma 95 (9.8)
Chronic obstructive pulmonary disease 183 (18.9)
Obesity 325 (33.5)
Diabetes mellitus 170 (17.5)
Chronic renal failure 86 (8.8)
Cardiac disease 106 (10.9)
Pregnancy 30 (3.1)
Haematological disease 74 (7.6)
HIV infection 20 (2.1)
Autoimmune disease 39 (4.0)
Complications, n (%)
Shock 555 (57.4)
Mechanical ventilation 787 (81.1)
Acute renal injury 251 (25.8)
Clinical and biomarkers
PCT ng/ml, median (IQR) 0.7 (0.2e2.9)
CRP mg/dl, median (IQR) 27 (14e90.2)
Vaccinated, n (%) 58 (8.2)
Quadrants infiltrated in chest X-ray
at ICU admission, mean (SD)
2.4 (1.3)
Time between diagnosis and
ICU admission, days, mean (SD)
2.4 (3.5)
Antibiotic treatment first day in ICU, n (%) 972 (100)
ICU Mortality, n (%) 242 (24.9)
Abbreviations: CARC: community-acquired respiratory coinfection; SD
unit; PCT: procalcitonin; CRP: C-reactive protein.
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of the true positives and true negatives results. Subse-
quently, we calculated pre-test probability, pre-test Odds
post-test Odds, post-test Odds, and post-test probability.
Statistical analysis with the CHAID method was carried
out through the CHAID node included in the statistical pro-
gram SPSS 20.0 for Windows (IBM).Results
Study population characteristics
Two thousand one hundred thirty-two patients with rt-PCR-
confirmed influenza A(H1N1)pdm09 virus infection were
admitted to the 148 ICUs in the three periods considered.
Nine hundred and seventy-two of them (45.6%) had PCT
levels measured upon admission to the ICU and were the
population of analysis. Of these patients, 581 (59.8%) were
men, and the median was 51 years of age. The mean
APACHE II and SOFA scores were 16.5 and 6.4 points,s among patients with proven influenza A(H1N1)pdm09 infec-
(CARC).
A(H1N1)pdm09 (n Z 776) CARC (n Z 196) p-value
50.8 (14.9) 52.7 (14.0) 0.12
51.0 (40e61) 53 (42e62)
451 (58.1) 130 (66.3) 0.03
15.0 (10e20) 18.0 (13e22) <0.001
6.0 (3e8) 7.0 (4e10) <0.001
569 (73.3) 143 (73.0) 0.86
78 (10.1) 17 (8.7) 0.55
142 (1.3) 41 (20.9) 0.41
273 (3.2) 52 (26.5) 0.02
135 (17.4) 35 (17.9) 0.89
66 (8.5) 20 (10.2) 0.46
90 (11.6) 16 (8.2) 0.16
28 (3.6) 2 (1.0) 0.61
56 (7.2) 18 (9.2) 0.35
13 (1.7) 7 (3.6) 0.09
31 (4.0) 8 (4.1) 0.19
416 (53.6) 139 (70.9) <0.001
624 (80.4) 163 (83.2) 0.41
175 (22.6) 76 (38.8) <0.001
0.5 (0.2e2.0) 2.4 (0.6e11.7) <0.001
25 (13.2e88.2) 38.5 (19.5e154) 0.62
42 (5.4) 16 (8.2) 0.18
2.5 (1.3) 2.4 (1.2) 0.20
2.3 (3.4) 2.6 (3.8) 0.53
776 (100) 196 (100) 1.0
179 (23.1) 63 (32.1) <0.01
: standard deviation; IQR: interquartile range; ICU: intensive care
CT) levels for ruling-out bacterial coinfection in ICU patients with
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Procalcitonin and bacterial coinfection 5respectively. Patients had a high comorbidity burden (see
detailed baseline characteristics in Table 1).
In comparison with the study population, patients
excluded from the analysis (n Z 1160) had less severity
of illness (APACHE II score Z 14.5 [7.1] p < 0.001; SOFA
score Z 5.59 [3.7] p < 0.001), were younger (48.0 [15.6]
p < 0.001) and had a lower ICU mortality rate (19.6%;
p < 0.001).
Primary viral pneumonia caused by influenza A(H1N1)
pdm09 without CARC was found in 776 patients (79.8%), and
196 patients (20.3%) had CARC with another isolated path-
ogen upon admission to the ICU. The etiological diagnosis of
CARCwas based on quantitative ETA (82.5%), urinary antigen
(13%), blood cultures (3.0%), and serology (1.5%); S. pneumo-
niae was the most prevalent isolated pathogen (99 patients;
50.5%), followed by Pseudomonas aeruginosa (17 patients;
8.7%), methicillin-sensitive Staphylococcus aureus (MSSA)
(16 patients; 8.2%), and Streptococcus pyogenes (10 pa-
tients; 5.1%). Table 2 details the prevalence of isolated path-
ogens in patients with CARC. Four patients (2%) had CARC
with more than one microorganism.
Compared with patients without CARC, patients with
CARC had higher APACHE II and SOFA scores upon admission.
No differences in comorbidities were observed except for
obesity, which was more common in patients without CARC.
Patients with CARC required more vasopressor and devel-
oped of acute renal failure more frequently than those
without it. Empirical AB therapy was administered to all
patients but CARC was associated with increased ICU
mortality. Demographic data and clinical characteristics
of patients with influenza A(H1N1)pdm09 infection, with
and without CARC, are presented in Table 1.
PCT and CRP diagnostic accuracy
Median values of PCT (2.4 ng/mL vs. 0.5 ng/mL), but not of
CRP (25 mg/dL vs. 38.5 mg/dL), were significantly higher inTable 2 Pathogens isolated in patients with A(H1N1)pdm09 viru
(CARC).
Pathogens N (%)
Streptococcus pneumoniae 99 (50.5)
Pseudomonas aeruginosa 17 (8.7)
MSSA 16 (8.2)
Streptococcus pyogenes 10 (5.1)
Aspergillus sp. 9 (4.6)
Acinetobacter baumannii 7 (3.6)
Escherichia coli 5 (2.6)
Klebsiella pneumoniae 4 (2.0)
Haemophilus influenza 4 (2.0)
Staphylococcus hominis 4 (2.0)
Chlamydia sp. 3 (1.5)
Moraxella catarrhalis 2 (1.0)
Enterococcus faecium 2 (1.0)
Serratia sp. 2 (1.0)
MRSA 2 (1.0)
Mycobacterium tuberculosis 2 (1.0)
Others 5 (2.6)
MSSA: methicillin-sensitive Staphylococcus aureus; MRSA: methicillin-
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ng/mL vs. 1.1 [0.4e4.3] ng/mL; p < 0.001), but not CRP
levels (26.3 [14.1e92.9] mg/dL vs. 27.0 [14.0e90.0] mg/dL;
pZ 0$71), were significantly higher in non-survivors than in
survivors. Fig. 1 shows the ROC curve of PCT and CPR. The
AUC was significantly higher for PCT (AUC 0.716 [95% CI
0.67e0.75]) than for CRP (AUC 0.590 [95% CI 0.54e63.0];
ZZ 4.25; p < 0.001). The results were similar when immu-
nocompromised patients were excluded (AUC 0.74 [95% CI
0.67e0.78] vs. 0.59 [95% CI 0.54e0.63], p < 0.001).
Table 3 shows the discriminatory performance of PCT at
different predefined cut-off points for detection of CARC.
In patients with PCT <0.25 ng/mL, the NPV was 92% for
excluding CARC. Interestingly, even considering the higher
cut-off point (PCT >1 ng/mL), NPV remained high (88.5%)
with a LR of 0.51.
CHAID classification tree
The analysis was conducted using CHAID decision tree
techniques for obtaining the best cut-off points for PCT.
We included CARC as a dependent variable and clinical
variables upon admission to the ICU (age, sex, comorbid-
ities, SOFA score, serum PCT, serum CRP, presence of
shock, number of quadrants with infiltrates on chest X-
ray, AKI, and mechanical ventilation) as independent vari-
ables in the model. Maximum tree depth was three, with
minimum cases in parent node of 100. A decision tree was
generated (Fig. 2) with seven terminal nodes and two levels
deep This analysis showed that PCT was the most decisive
variable at the time of classification and four levels of
risk for CARC were generated: 1) very-low-risk (PCT
<0.29 ng/mL); 2) low risk (PCT 0.29e1.10 ng/mL); 3) inter-
mediate risk (>1.10e4.42 ng/mL); and 4) high risk (PCT
>4.42 ng/mL).
According to these ranges, we established three cut-off
points to calculate the discriminatory performance of PCT.s infection with community-acquired respiratory coinfection
Definitive Probable
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resistant Staphylococcus aureus.
PCT) levels for ruling-out bacterial coinfection in ICU patients with
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Figure 1 Area under the receiver operating characteristic
(AUC) curves of procalcitonin (PCT) and C-reactive protein
(CRP) for differentiation of patients with community-
acquired respiratory coinfection (CARC) from primary viral
infection.
6 A.H. Rodrı´guez et al.Only PCT >4.42 ng/mL showed high specificity for CARC
(85.4%), but the LRþ was low (2.8) with pre-test Odds of
0.25 and both post-test Odds of 0.73 and a post-test
probability of 42%. Conversely, a cut-off of PCT <0.29 ng/
mL was associated with an S of 88.2%, an Sp of 33.2%, and a
PPV of 25% but with a high NPV (91.8%). For a probability
pre-test of 20%, the pre-test Odds were 0.25 and post-test
Odds of 0.09 with an 8% post-test probability of CARC.
In the very-low-risk level, the absence of shock
improved classification capacity. Thus, for a cut-off of
PCT <0.29 ng/mL, when patients without shock were
considered (n Z 412), the S was 84%, the Sp 43% and the
pre-test probability of CARC, 14%. This cut-off had a PPV of
19% and a NPV of 94% with a LRþ of 1.49 and LR of 0.36. In
this condition, pre-test Odds were 0.16 and post-test Odds
0.06, with only a 6% post-test probability of CARC. TheTable 3 Discriminatory performance of procalcitonin (PCT) cut-
infection (CARC) in patients with influenza A(H1N1)pdm09 infect
Variable Cut-off point Sensitivity,
% (95% CI)
Specificity,
% (95% CI)
PCT algorithms9 <0.25 ng/mL 89.7 (84.9e93.1) 31.3 (28.3e
<0.50 ng/mL 78.0 (72.0e8.30) 46.5 (43.2e
<0.75 ng/mL 70.5 (64.1e76.2) 58.6 (55.3e
>1.0 ng/mL 66.8 (60.3e72.8) 64.9 (61.7e
PCT CHAID <0.29 ng/mL 88$2 (83$0e92$0) 33.2 (30.0e
<1.10 ng/mL 65$8 (58$9e72$0) 65.8 (62.4e
>4.42 ng/mL 41$8 (35$1e48$8) 85.4 (82.7e
CI: confidence interval; PPV: positive predictive value; NPV: negative
likelihood ratio.
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off of PCT 1.10 ng/mL in patients without shock.Discussion
The main findings of our study conducted in patients with
confirmed A(H1N1)pdm09 virus infection were threefold.
First, the CHAID model illustrates multilevel interactions
among risk factors to identify stepwise pathways to detect
CARC. The proposed CHAID model distributed serum PCT
into the first level of partition above other variables as the
strongest variable associated with CARC. Second, low
serum levels of PCT in patients without shock were an
accurate predictor for excluding the presence of CARC
(<6%) and finally, PCT was more accurate than CRP, which
is still the standard biomarker routinely used in many ICUs
to define the presence of CARC.
The CHAID model illustrates multilevel interactions
among risk factors to identify stepwise pathways for
detecting CARC. CHAID models seem to be a promising tool
to detect CARC and assist in clinical decision-making that, to
our best of our knowledge, has not been proposed before.
Previous studies focussing on the ability of PCT or CRP to
discriminate between A(H1N1)pdm09 viral and bacterial
coinfection have significant shortcomings, limiting their
applicability to the scenarios currently faced by intensiv-
ists. Several studies11e14 and recent meta-analysis15 sug-
gest that PCT is more accurate than CRP for distinguishing
between viral and bacterial infection. However, perfor-
mance varies depending on microbial factors, severity of
illness and the cut-off points used. Interestingly, in our
study, PCT levels were significantly increased in patients
with CARC compared to those with primary viral pneu-
monia, but CRP was not. The overall discriminatory perfor-
mance of PCT for identifying CARC was moderate, with an
AUC of 0.71, but better discrimination than CRP for detect-
ing bacterial infection, similar to that reported in other
studies.27,28
Antimicrobial overuse in ICU patients with viral pneu-
monia caused by influenza A(H1N1)pdm09 could be sub-
stantially reduced if AB treatment were restricted to those
patients with a true CARC. The application to our popula-
tion of the classically reported algorithm cut-off point
(>0.5 ng/mL)9 yields modest results with S of 78%, low Spoff point for detection of community-acquired respiratory co-
ion.
PPV, % (95% CI) NPV, % (95% CI) LR (þ) LR ()
34.5) 24.8 (21.9e28.0) 92.0 (88.6e94.8) 1.30 0.32
49.8) 26.9 (23.6e30.6) 89.3 (86.0e91.8) 1.45 0.47
61.8) 30.1 (26.3e43.3) 88.7 (85.8e91.0) 1.70 0.50
68.1) 32.5 (28.3e37.0) 88.5 (85.8e90.8) 1.90 0.51
36.6) 25.0 (21.9e28.4) 91.8 (88.0e94.5) 1.32 0.35
691) 32.7 (28.3e37.5) 88.4 (85.5e90.7) 1.92 0.51
87.7) 42.0 (35.3e49.0) 85.3 (82.6e87.6) 2.8 0.68
predictive value; LR(þ): positive likelihood ratio; LR(): negative
CT) levels for ruling-out bacterial coinfection in ICU patients with
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Node 0
Category          %          n
No                 79·8       776
Yes                 20·2      196
Total              100·0    972
Co-infec?on 
Node 1
Category          %          n
No                 91·6       261
Yes                   8·4         24
Total              29·3       285
Node 2
Category          %          n
No                  84·8      256
Yes                 15·2        46
Total              31·1      302
Node 3
Category          %          n
No                 76·4       146
Yes                 23·6         45
Total              19·7       191
Node 4
Category          %          n
No                 58·2       113
Yes                 41·8         81
Total              20·0       194
PCT
Adj. p-value = 0·000 Chi-
squared=86·50, df=3
<0·29 0·29 – 1·10 1·10 – 4·42 >4·42 
Node 9
Category          %          n
No                 71·1         64
Yes                 29·9         26
Total                9·3         90
Node 10
Category          %          n
No                 47·1         49
Yes                 52·9         55
Total              10·7       104
CRP
Adj. p-value = 0·013 
Chi-squared=11·60, 
df=1
<26·7 >26·7 
Node 7
Category          %          n
No                  93·7       118
Yes                   6·3            8
Total              13·0        126
Node 8
Category          %          n
No                 78·4        138
Yes                21·6          38
Total             18·1        176 
Shock
Adj. p-value = 0·000 Chi-
squared=14·51, df=1
NO Yes 
Very Low Risk Low Risk Intermediate Risk High Risk
Node 5
Category          %          n
No                 94·5        156
Yes                  5·5             9
Total             17·0        165
Node 6
Category          %          n
No                  87·5        105
Yes                 12·5          15
Total              12·3        120
Shock
Adj. p-value = 0·03 Chi-
squared=4·41, df=1
NO Yes 
Figure 2 Tree created by the CHAID model (Chi-squared Automatic Interaction Detection) for community-acquired respiratory
coinfection (CARC). PCT: procalcitonin; CRP: C-reactive protein.
Procalcitonin and bacterial coinfection 7(46%), and very low PPV (27%), but a high NPV (89%). When
the cut-off point was raised to >1.0 ng/mL, Sp improved
somewhat (65%), but PPV remained low (32%). Even consid-
ering this relatively high cut-off point, the NPV remains high
(88%) with a low LRþ of 1.90.
A novel approach in searching for tools that could
improve the predictive capacity is to conduct a CHAID
decision-tree analysis. The main conceptual difference is
that, in this model, the interaction of the different vari-
ables was analysed. Thus, the hazard ratio applies to the
whole population rather than to a single subgroup. This
methodology has the ability to improve the predictive
capacity achieved by multivariate models in specific situ-
ations. In particular, the CHAID method allows the detec-
tion of individual cases with unique behaviour within the
study population as a whole that would have gone unno-
ticed using conventional methods.16e19
After applying this method, our study showed that the
most decisive variable at the time of classification was the
level of PCT, with a discriminative value greater than other
clinical variables such as the presence of shock, or the level
of CRP. According to the PCT CHAID-generated cut-off
point, a PCT test, even above 4.42 ng/mL, exhibited a
suboptimal rule-in value for confirming CARC. The overall
LRþ (2.8) for the PCT test was not sufficiently high to be
used as a reliable rule-in tool for the diagnosis of CARC. For
example, in our population with a 20% prevalence (pre-test
probability) of CARC, a LRþ of 2.8 translates into a positive
predictive value (post-test probability) of 42%. In other
words, approximately 2 out of 5 patients with positive PCT
test results would have either clinically- or
microbiologically-confirmed CARC.Please cite this article in press as: Rodrı´guez AH, et al., Procalcitonin (
influenza: A CHAID decision-tree analysis, J Infect (2015), http://dx.dConversely, the serum levels of PCT showed acceptable
ability to rule out the presence of CARC in patients with
H1N1pdm09 virus infection. Applying a cut-off point of
<0.29 ng/mL to the same population with a 20% prevalence
of CARC, a LR of 0.35 translates into a NPV of 92% with an
8% post-test probability of CARC. This probability decreased
to 6% in patients without shock even when the PCT cut-off
point was increased to 1.10 ng/mL. In other words, only 1
out of every 20 patients with a negative PCT result would
have either clinically- or microbiologically-confirmed CARC.
Even if another study is required to validate of our
findings before a specific recommendation can be made,
our results suggest that in the absence of shock, serum PCT
values 1.10 ng/mL are associated with a low probability of
the presence of CARC in patients without shock. We
acknowledge that some physicians might feel uncomfort-
able if an ICU patient who had a PCT 0.29 ng/mL (and
therefore still with a 6% chance of having CARC) were left
untreated. In approaching this clinical situation, one might
decide to treat empirically since a negative test does not
rule out disease. Alternatively, one could perform a new
determination of serum PCT in the next 24 h and closely
observe the patient before starting antibiotic treatment.
Modifying patient-based antibiotic treatment is an ever-
changing responsibility of the antimicrobial stewardship
programme whose purpose is to limit inadequate antimi-
crobial use, bacterial resistance, unnecessary cost, and
possible harm to patients. As a diagnostic tool, serum PCT
levels might assist physicians in stratifying patients accord-
ing to the risk of CARC.
There are some limitations that should be taken into
account. First, serial measurements of the serum PCTPCT) levels for ruling-out bacterial coinfection in ICU patients with
oi.org/10.1016/j.jinf.2015.11.007
8 A.H. Rodrı´guez et al.values were not performed. Although serial measurements
have been previously proposed, and could potentially
improve discriminative values, our results showed that
the initial value of PCT is useful to guide the decision
regarding the need to start antibiotic treatment upon
admission to the ICU. Second, there is currently no gold
standard for the diagnosis of CARC. The incidence of CARC
in our study is consistent with what has been previously
reported.6,8 We did not collect information on AB adminis-
tration prior to admission of the ICU. The sensitivity of res-
piratory cultures after starting AB might be very low, and
we cannot rule out that a portion of the respiratory cultures
may be false negative. However, all patients included had
microbiological confirmation of CARC. On the other hand,
it is true that negative rt-PCR for influenza test does not
exclude viral pneumonia in 100% of cases, but the published
overall sensitivity of rt-PCR for viral diagnosis is very high
(>98%), with a high negative predictive value (99.8%).29
Conversely, a false negative rt-PCR result may occur if inad-
equate numbers of organisms are present in the specimen
due to improper collection, transport or handling or if an
excess of DNA/RNA template is present in the reaction.
For the purpose of our study, in order to minimize biased
selection, these patients were excluded from the study.
Third, the measurement of PCT was made at the discretion
of the attending physician, and patients in whom PCT was
determined were more severely ill than those in which
this marker was not obtained However, this is the “actual
and current” clinical picture in daily practice, and could
reflect a greater difficulty in the diagnosis of CARC in the
most severe patients, in which situation biomarker levels
could play a more important role. We acknowledge the ur-
gent need for conducting subsequent intervention studies
where antibiotic therapy is guided by the use of PCT.
Further large randomized studies are needed to clarify
the impact of CHAID algorithms in clinical practice in pa-
tients with viral pneumonia.
Fourth, although the CHAID method has great advan-
tages, an information overload could occur due to a large
quantity of terminal nodes but few patients in each node.
In this study, we imposed a very strict model to imple-
ment a p value <0.05 and at least restricted to 100
patients per node, and the resulting final tree can be
easily interpreted and is clinically applicable with only
seven terminal nodes. Our results cannot be generalised
to other clinical scenarios such as the emergency depart-
ment and other viral strains causing pneumonia. In these
situations, the inflammatory response and biomarkers
may differ depending on clinical severity and the under-
lying viral pathogen.Conclusion
In patients admitted to the ICU with confirmed influenza
A(H1N1)pdm09 infection and without shock, low serum
levels of PCT might be a good tool for ruling out the
presence of CARC. However, while PCT can assist physicians
in developing patient-specific therapeutic plans, such as
antibiotic prescription, it is important to highlight that
biomarkers are tools that should never replace physician
decision-making.Please cite this article in press as: Rodrı´guez AH, et al., Procalcitonin (P
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